Work

Supplementary Figure S6 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S6 shows additional analysis of seribantumab efficacy in the ovarian cancer PDX OV-10-0050
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362432264
Cites:
Cited by:
Related to: 10